5H-thiazolo[3,2-c]pyrimidine-5,7(6H)-dione | 449798-84-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 5H-thiazolo[3,2-c]pyrimidine-5,7(6H)-dione
• 英文别名: Thiazolo[3,2-c]pyrimidine-5,7-dione；[1,3]thiazolo[3,2-c]pyrimidine-5,7-dione
• CAS: 449798-84-9
• 化学式: C₆H₄N₂O₂S
• 分子量: 168.176
• InChiKey: PAFDIRLMHIGRDZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  74.7
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5H-thiazolo[3,2-c]pyrimidine-5,7(6H)-dione 、 Dicaesio carbonate 、 3,4-二氯氯苄 在 N,N-二甲基甲酰胺 、 乙酸乙酯 、 silica gel 、 二氯甲烷 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 20.25h， 以EtOAc, 19:1 to give 1.252 g (64%) of 6-(3,4-Dichlorobenzyl)-thiazolo[3,2-c]pyrimidine-5,7-dione的产率得到6-(3,4-dichlorobenzyl)-thiazolo[3,2-c]pyrimidine-5,7-dione
  参考文献：
  名称：

  BICYCLIC PYRIMIDINE MATRIX METALLOPROTEINASE INHIBITORS

  摘要：

  选择性MMP-13抑制剂是公式I的双环嘧啶或其药学上可接受的盐，其中R1为氢或烷基；R2，R3和R4包括氢，卤素，烷基，C≡C（CH2）芳基，CO2烷基，CO2（CH2）芳基，COHN烷基和CONH（CH2）芳基；X为O，S，SO，SO2，CH2，C═O，CHOH，NH或NR5。公式I的化合物或其药学上可接受的盐，可用于治疗癌症或关节炎。

  公开号：

  US20060040957A1
• 作为产物：
  描述：

  (2,6-dioxo-1,2,3,6-tetrahydropyrimidine-4-yl-sulfanyl)-acetaldehyde dimethyl acetal 在 碘代三甲硅烷 作用下， 生成 5H-thiazolo[3,2-c]pyrimidine-5,7(6H)-dione
  参考文献：
  名称：

  [EN] CYCLIC COMPOUNDS CONTAINING ZINC BINDING GROUPS AS MATRIX METALLOPROTEINASE INHIBITORS
  [FR] COMPOSES CYCLIQUES CONTENANT DES GROUPES LIANT LE ZINC EN TANT QU'INHIBITEURS DE METALLOPROTEASE DE MATRICE

  摘要：

  公开号：

  WO2004014384A3

文献信息

• SUBSTITUTED TETRAHYDROCARBAZOLE AND CARBAZOLE CARBOXAMIDE COMPOUNDS
  申请人：Bristol-Myers Squibb Company

  公开号：US20140378475A1

  公开（公告）日：2014-12-25

  Disclosed are compounds of Formula (I) wherein: the two dotted lines represent either two single or two double bonds; Q is: R 1 is F, Cl, —CN, or —CH 3 ; R 2 is Cl or —CH 3 ; R 3 is —C(CH 3 ) 2 OH or —CH 2 CH 2 OH; R a is H or —CH 3 ; each R b is independently F, Cl, —CH 3 , and/or —OCH 3 ; and n is zero, 1, or 2. Also disclosed are methods of using such compounds as inhibitors of Bruton's tyrosine kinase (Btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

  公开的是Formula (I)的化合物，其中：两条虚线代表两个单键或两个双键；Q是：R1是F、Cl、—CN或—CH3；R2是Cl或—CH3；R3是—C(CH3)2OH或—CH2CH2OH；Ra是H或—CH3；每个Rb独立地是F、Cl、—CH3和/或—OCH3；n为零、1或2。还公开了将这些化合物用作Bruton酪氨酸激酶（Btk）抑制剂的方法，以及包含这些化合物的药物组合物。这些化合物在治疗、预防或减缓多种治疗领域的疾病或疾病的进展方面非常有用，如自身免疫疾病和血管疾病。
• Cyclic compounds containing zinc binding groups as matrix metalloproteinase inhibitors
  申请人：——

  公开号：US20040063673A1

  公开（公告）日：2004-04-01

  This invention provides compounds defined by Formula I Z—L—R 1 —Q—D—(V 1 ) m —R 2 I or a pharmaceutically acceptable salt thereof, wherein Z, L, R 1 , Q, D, V 1 , m, and R 2 are as defined in the specification. The invention also provides pharmaceutical compositions comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, as defined in the specification, together with a pharmaceutically acceptable carrier, diluent, or excipient. The invention also provides methods of inhibiting an MMP-13 enzyme in an animal, comprising administering to the animal a compound of Formula I, or a pharmaceutically acceptable salt thereof. The invention also provides methods of treating a disease mediated by an MMP-13 enzyme in a patient, comprising administering to the patient a compound of Formula I, or a pharmaceutically acceptable salt thereof, either alone or in a pharmaceutical composition. The invention also provides methods of treating diseases such as heart disease, multiple sclerosis, osteo- and rheumatoid arthritis, arthritis other than osteo- or rheumatoid arthritis, cardiac insufficiency, inflammatory bowel disease, heart failure, age-related macular degeneration, chronic obstructive pulmonary disease, asthma, periodontal diseases, psoriasis, atherosclerosis, and osteoporosis in a patient, comprising administering to the patient a compound of Formula I, or a pharmaceutically acceptable salt thereof, either alone or in a pharmaceutical composition. The invention also provides combinations, comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, together with another pharmaceutically active component as described in the specification.

  本发明提供了由式子IZ—L—R1—Q—D—（V1）m—R2或其药学上可接受的盐所定义的化合物，其中Z，L，R1，Q，D，V1，m和R2在规范中有定义。本发明还提供了制药组合物，包括由规范中定义的式子I或其药学上可接受的盐所定义的化合物，以及药学上可接受的载体、稀释剂或赋形剂。本发明还提供了抑制动物中MMP-13酶的方法，包括向动物投与式子I或其药学上可接受的盐所定义的化合物。本发明还提供了治疗患有由MMP-13酶介导的疾病的患者的方法，包括向患者投与式子I或其药学上可接受的盐所定义的化合物，单独使用或在制药组合物中使用。本发明还提供了治疗心脏病、多发性硬化症、骨关节炎和类风湿性关节炎、非骨关节炎或类风湿性关节炎的关节炎、心力衰竭、炎症性肠病、老年性黄斑变性、慢性阻塞性肺疾病、哮喘、牙周疾病、银屑病、动脉硬化和骨质疏松症的患者的方法，包括向患者投与式子I或其药学上可接受的盐所定义的化合物，单独使用或在制药组合物中使用。本发明还提供了由式子I或其药学上可接受的盐所定义的化合物与规范中描述的另一种药物活性成分的组合。
• SUBSTITUTED TETRAHYDROCARBAZOLE AND CARBAZOLES CARBOXAMIDE COMPOUNDS
  申请人：Bristol-Myers Squibb Company

  公开号：US20160194338A1

  公开（公告）日：2016-07-07

  Disclosed are compounds of Formula (I) wherein: the two dotted lines represent either two single or two double bonds; Q is: R 1 is F, Cl, —CN, or —CH 3 ; R 2 is C 1 or —CH 3 ; R 3 is —C(CH 3 ) 2 OH or —CH 2 CH 2 OH; R a is H or —CH 3 ; each R b is independently F, Cl, —CH 3 , and/or —OCH 3 ; and n is zero, 1, or 2. Also disclosed are methods of using such compounds as inhibitors of Bruton's tyrosine kinase (Btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

  本发明涉及式（I）的化合物，其中：两个点状线代表两个单键或两个双键；Q为：R1为F、Cl、—CN或—CH3；R2为C1或—CH3；R3为—C(CH3)2OH或—CH2CH2OH；Ra为H或—CH3；每个Rb独立地为F、Cl、—CH3和/或—OCH3；n为零、1或2。本发明还涉及使用这些化合物作为布鲁顿酪氨酸激酶（Btk）抑制剂的方法，以及包含这些化合物的制药组合物。这些化合物在治疗、预防或减缓多种治疗领域的疾病或疾病进展方面是有用的，例如自身免疫性疾病和血管疾病。
• CARBAZOLE CARBOXAMIDE COMPOUNDS
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20160200710A1

  公开（公告）日：2016-07-14

  Disclosed are compounds of Formula (I); and salts thereof, wherein: Formula (II); Q is: R 1 is —C(CH 3 )2OH, —NHC(=0)C(CH 3 ) 3 , —N(CH3)2, or —CH 2 R d ; R 2 is CI or —CH 3 ; R 3 is H, F, or —CH 3 ; R a is H or —CH 3 ; R b is H, F, CI, or —OCH3 R c is H or F; and Rd is —OH, —OCH3, —NHC(=0)CH3, or fORMULA (III), Also disclosed are methods of using such compounds as inhibitors of Bruton's tyrosine kinase (Btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

  本发明涉及式（I）化合物及其盐，其中：式（II）；Q为：R1为—C（CH3）2OH，—NHC（=0）C（CH3）3，—N（CH3）2或—CH2Rd；R2为CI或—CH3；R3为H，F或—CH3；Ra为H或—CH3；Rb为H，F，CI或—OCH3；Rc为H或F；Rd为—OH，—OCH3，—NHC（=0）CH3或式（III），还公开了使用这些化合物作为Bruton酪氨酸激酶（Btk）抑制剂的方法以及包含这些化合物的制药组合物。这些化合物在多种治疗领域中，如自身免疫疾病和血管疾病中，用于治疗、预防或减缓疾病或疾病的进展。
• Method for controlling the plasma level of lipoproteins
  申请人：NEDERLANDSE ORGANISATIE VOOR TOEGEPAST-NATUURWETENSCHAPPELIJK ONDERZOEK TNO

  公开号：EP0875247A1

  公开（公告）日：1998-11-04

  A compound which is an antagonist of platelet activating factor (PAF-antagonist) or a structurally related compound thereof not having PAF-antagonistic activity can be used for decreasing the plasma level of lipoprotein(a) and/or increasing the plasma level of high-density lipoprotein. The compound may be an azepine derivative, especially a benzo- or thienotriazolo-diazepine derivative, a diphenyl-tetrahydrofuran or diphenyldioxolane derivative or a tetrahydrofuran phospholipid analogue.

  血小板活化因子拮抗剂（PAF-antagonist）化合物或其结构相关的不具有 PAF 拮抗活性的化合物可用于降低血浆中脂蛋白（a）的水平和/或提高血浆中高密度脂蛋白的水平。该化合物可以是氮杂卓衍生物，特别是苯并三唑或噻吩三唑-二氮杂卓衍生物、二苯基四氢呋喃或二苯基二氧戊环衍生物或四氢呋喃磷脂类似物。